Central Effects of Ivermectin in Alleviation of Covid-19-induced Dysauto-nomia.
Curr Drug Targets
; 23(13): 1277-1287, 2022.
Article
in English
| MEDLINE | ID: covidwho-2098966
ABSTRACT
Covid-19 may be associated with various neurological disorders, including dysautonomia, a dysfunction of the autonomic nervous system (ANS). In Covid-19, hypoxia, immunoinflammatory abnormality, and deregulation of the renin-angiotensin system (RAS) may increase sympathetic discharge with dysautonomia development. Direct SARS-CoV-2 cytopathic effects and associated inflammatory reaction may lead to neuroinflammation, affecting different parts of the central nervous system (CNS), including the autonomic center in the hypothalamus, causing dysautonomia. High circulating AngII, hypoxia, oxidative stress, high pro-inflammatory cytokines, and emotional stress can also provoke autonomic deregulation and high sympathetic outflow with the development of the sympathetic storm. During SARS-CoV-2 infection with neuro-invasion, GABA-ergic neurons and nicotinic acetylcholine receptor (nAChR) are inhibited in the hypothalamic pre-sympathetic neurons leading to sympathetic storm and dysautonomia. Different therapeutic modalities are applied to treat SARS-CoV-2 infection, like antiviral and anti-inflammatory drugs. Ivermectin (IVM) is a robust repurposed drug widely used to prevent and manage mild-moderate Covid-19. IVM activates both GABA-ergic neurons and nAChRs to mitigate SARS-CoV-2 infection- induced dysautonomia. Therefore, in this brief report, we try to identify the potential role of IVM in managing Covid-19-induced dysautonomia.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Primary Dysautonomias
/
COVID-19
Type of study:
Experimental Studies
Limits:
Animals
/
Humans
Language:
English
Journal:
Curr Drug Targets
Journal subject:
Drug Therapy
Year:
2022
Document Type:
Article
Affiliation country:
1389450123666220810102406
Similar
MEDLINE
...
LILACS
LIS